Connecticut biotech Biodel ($BIOD) is touting mid-stage results for its long-acting insulin, as the in-development BIOD-531 better controlled glucose than two Eli Lilly ($LLY) therapies. In a study on Type 2 diabetics with moderate insulin resistance, Biodel's drug beat out Lilly's Humalog and Humulin in controlling blood sugar after two meals, the company said. Biodel said it's now working with the FDA to design a late-stage program and move BIOD-531 both for insulin-resistant patients and broader populations. More